MedTrace Logo

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

NCT02219178 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-07-17

No results posted yet for this study

Summary

This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.

Conditions

Interventions

DRUG

lenalidomide

25mg days 1 - 14 of 21 day schedule

DRUG

Subcutaneous bortezomib

1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule

DRUG

Dexamethasone

20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Principal Investigators

  • Peter O'Gorman, Dr · Mater Misericordiae University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2019-10-31
Completion
2020-04-30

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02219178 on ClinicalTrials.gov